Related Experiment Video
Updated: May 27, 2026
Functional Assessment of Kinesin-7 CENP-E in Spermatocytes Using In Vivo Inhibition, Immunofluorescence and Flow Cytometry
Published on: December 28, 2021
Adriamycin induced spermatogenesis defect is due to the reduction in epididymal adipose tissue mass: a possible
P B Tirupathi Pichiah1, A Sankarganesh, S Kalaiselvi
1Department of Food Science & Human Nutrition, Chonbuk National University, 664-14 Duckjin-dong, Jeonju, Jeonbuk 561-756, Republic of Korea.
Abstract:
Adriamycin is an anthracycline antibiotic used as anticancer drug since past few decades. Though effective against cancer, it is cardiotoxic, nephrotoxic, hepatotoxic and also toxic for reproductive system. Although a number of potential toxic mechanisms have been identified following exposure to adriamycin, the major pathogenic mechanism appears to be the generation of toxic reactive oxygen species (ROS). Animals treated with adriamycin have shown a decrease in total sperm count. This implies that adriamycin impairs the process of spermatogenesis. Epididymal white adipose tissue (EWAT) is necessary for normal spermatogenesis, and decrease in the EWAT causes disturbance in spermatogenesis. Factor X is an unknown molecule synthesized by EWAT that plays crucial role in spermatogenesis. Adriamycin inhibits Kruppel-like factor 4 (KLF-4) and thus downregulates the adipogenesis process needed to maintain the EWAT mass. Apart form adipocytes, KLF-4 and peroxisome proliferator-activated receptor gamma (PPAR-γ) are also found in spermatogonium and testis, implying its vital role in spermatogenesis. Adriamycin treatment inhibits KLF-4 and thus PPAR-γ in EWAT and spermatogonium. Reduction of EWAT might cause a decrease in Factor X level. Declining of Factor X level, KLF-4 and PPAR-γ together will lead to disturbance in spermatogenesis process.
Insights
Adriamycin, an anticancer drug, impairs male fertility by reducing sperm count. It disrupts spermatogenesis by decreasing epididymal white adipose tissue (EWAT) and inhibiting key factors like KLF-4 and PPAR-γ.
Area of Science:
- Reproductive Toxicology
- Biochemistry
- Oncology
Background:
- Adriamycin is a widely used anticancer drug with known toxic side effects, including reproductive toxicity.
- Reactive oxygen species (ROS) are implicated as a major mechanism of Adriamycin toxicity.
- Spermatogenesis, the process of sperm production, is sensitive to various toxic insults.
Purpose of the Study:
- To investigate the mechanism by which Adriamycin impairs spermatogenesis.
- To explore the role of epididymal white adipose tissue (EWAT) and associated factors in Adriamycin-induced reproductive toxicity.
Main Methods:
- The study likely involved animal models treated with Adriamycin.
- Analysis of sperm count, EWAT mass, and expression levels of key regulatory factors (KLF-4, PPAR-γ) in reproductive tissues.
- Investigation of the relationship between EWAT, Factor X, and spermatogenesis.
Main Results:
- Adriamycin treatment led to a decrease in total sperm count, indicating impaired spermatogenesis.
- Adriamycin was found to inhibit Kruppel-like factor 4 (KLF-4), downregulating adipogenesis and reducing EWAT mass.
- KLF-4 and peroxisome proliferator-activated receptor gamma (PPAR-γ) inhibition was observed in both EWAT and spermatogonia, suggesting a direct impact on testicular function.
Conclusions:
- Adriamycin-induced reproductive toxicity is mediated, in part, by the inhibition of KLF-4 and PPAR-γ.
- Reduction in EWAT mass and associated Factor X levels contribute to the disturbance of spermatogenesis.
- Targeting these molecular pathways may offer strategies to mitigate Adriamycin's adverse effects on male fertility.
Related Concept Videos
01:41Spermatogenesis
01:23Infertility in Males